RxDoctor Payments Data

Laurie Wenger, MD

Ophthalmology · Potomac, MDNPI 1386643120

Payments from drug & device makers

$964in general payments, 2019–2025

Across 37 payments — averaging $26.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$374
  • Bausch & Lomb Americas Inc.$178
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$144
  • Sun Pharmaceutical Industries Inc.$120
  • Coopervision Inc.$43
  • Johnson & Johnson Vision Care, Inc.$27
  • plus $78 from 4 others

What the payments were for

  • Food & beverage$94698%
  • Education$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$964 in reported general payments places this provider in the 45th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$169,870
Medicare patients
593
Services billed
1,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine84$121,115
MieboPerfluorohexyloctane/Pf49$41,499
LumiganBimatoprost45$28,233
XiidraLifitegrast11$18,283
VyzultaLatanoprostene Bunod29$16,894
RocklatanNetarsudil Mesylat/Latanoprost20$9,107
CombiganBrimonidine Tartrate/Timolol21$7,826
Cyclosporine13$5,096
Loteprednol Etabonate21$4,493
Brinzolamide12$3,290
Dorzolamide-TimololDorzolamide/Timolol/Pf11$3,044
Brimonidine Tartrate11$2,974
Bromfenac Sodium21$2,592
Prednisolone Acetate33$1,920
MoxifloxacinMoxifloxacin Hcl47$1,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$25$157,174150 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$178$76,67689 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$144$4,49321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Potomac

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →